🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASCO25 CM901 in mUC, shows the arm of IO IO in inelegible cisplatin patients and the combo doesn’t improve OS compared to carbo gem, however interesting data on the responders OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 JAVELIN bladder medley phase 2 trial using avelumab and sacituzumab vs avelumab shows a very interesting positive PFS results in mUC, OS is not yet accomplished and suggest a rol of combo antitrop2 OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget

#ASCO25 EV302 Data on responders in those patients with mUC, can we talk about cure? Impressive data on responders, long survivors, appropriate dose reductions must be done to improve QOL and reduce toxicity@oncodaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com🦾🦾🦾

#ASCO25 great discussion on mUC highlighting the posible role on anti trop2 therapy, EV302 maintains the SOC in MUC OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 NIAGARA analysis in miUC using ctDNA, shows a promising opportunity as a predictive tool, showing once again a strong prognosis tool, we need to include these tools to personalise treatment OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 CM214 mRCC patients keeps showing amazing results after 9 year of treatment, nearly 30% maintains the benefit, long survivors 🍾 🥳 🙌🏻 🪅OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 new players in the management of mRCC patients with casdatifan plus a great TKI, shows similar data on toxicity compared to others antihif therapies. OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

We need such data urgently also for extra-pulmonary neuroendocrine cancers!

#ASCO25 magnitude trial,showing a different phenotype of mCSPC, positive results in rPFS, including the results of capture trial, we can be talking about a different disease HRR + 🥳 analyzing data OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 IRONMAN register shows that deep responses in PSA mainly those < 0.2 mg/dl have a better prognosis, and brings an excellent proposal to de-escalation therapy in those patients OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 aranote trial analysis in HRQOL, shows an improvement in QOL and delay to develop symptomatic disease mainly in ultralow patients OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 PTEN inactivation could be a predictive tool in those metastasic patients in mCSPC, only prognosis in local advanced disease, challenges in correlation with IHQ vs transcriptomic results OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 ARCHES trial showed advantage in OS with enzalutamide plus ADT vs ADT alone benefit includes high volume disease OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 COMRADE TRIAL phase 2 study shows an improvement in rPFS in patients heavily pretreated in mCRPC scenario, combining olaparib and radium223 mainly in those patients with HRR positive disease OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

#ASCO25 intensification therapy in AVPC with carboplatin cabazitaxel and determinan and maintainance with niraparib cetrelimab shows an improvement in mOS and mPFS with the combination OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget 🦾🦾🦾

Martin ZapataLaguado OncoDaily OncoAlert Asociación Colombiana de Hematología y Oncología Sociedad Colombiana de Urología UroToday.com UroTarget Great results in a really hard to treat population!!

#ASCO2025 was filled with groundbreaking science. Feeling inspired and grateful to be part of this community. These are just a few of the top breast cancer studies presented, and some of the remaining questions.

Presented at #ASCO25 Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive #ProstateCancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes meetings.asco.org/abstracts-pres… The

Thanks to Asociación Colombiana de Hematología y Oncología for letting us do this first symposium on CNS primary disease! Urgent need to do more activities like this, Neurooncology is also moving towards GEINO EANO SNO OncoDaily OncoAlert Society for Neuro-Oncology Latin America 🦾🦾🦾

En la jornada, el grupo multidisciplinar junto con asociaciones de pacientes presentaron ante los portavoces parlamentarios de sanidad las propuestas fundamentales para mejorar el abordaje de esta enfermedad. Participaron GEINO, SENEC, SEAP-IAP, SEHOP, SEN, SENR, SEOR y GETTHI